Research progress in targets and challenges of antibody-drug conjugates in treatment of glioblastoma

VernacularTitle:抗体偶联药物在胶质母细胞瘤治疗中的作用靶点研究进展与挑战
Author: Kai LIU ¹ ; Yuchao DONG ; Yue LIU ; Hang ZHANG ; Song MIAO ; Chengyuan MA ; Zihao WANG
Author Information

1. 吉林大学第一医院,吉林长春 130012
Publication Type:Journal Article
Keywords: antibody-drug conjugates; glioblastoma; precision treatment
From: Chinese Journal of Pharmacology and Toxicology 2024;38(12):945-951
CountryChina
Language:Chinese
Abstract: Glioblastoma (GBM) is an exceptionally aggressive tumor that originates in the brain,characterized by a notably high mortality rate and a limited responsiveness to pharmacological interven-tions.In recent years,antibody-drug conjugates (ADCs) have emerged as a focal point in the advance-ment of anti-cancer therapeutic research,merging the precise targeting capabilities of antibodies with the powerful killing power of cytotoxins.In recent years,the outcomes of numerous clinical trials investi-gating ADCs targeted against GBM have been notably encouraging.This article endeavors to provide a comprehensive overview of the prevalent ADCs targets for GBM therapy,which include the epidermal growth factor receptor,the cluster of differentiation,the mannose receptor family,the integrin family,and the galectin family.Furthermore,it will delve into the contemporary landscape of ADCs drug research and the significant challenges encountered in the application of ADCs for GBM treatment.